

X-Waiver Training for MAT Treatment Prescription

Thursday, November 29, 2018 1pm - 5pm

Partnership HealthPlan - Santa Rosa Conference Room

495 Tesconi Circle, Santa Rosa, CA 95401

Register online for
FREE X-Waiver training:

www.eventbrite.com/e/x-waiver-training-tickets-50666565060

AAAP is the Data Sponsor for this training



Target Audience: MD's, DO's, NP's, PA's, interested in obtaining DEA "X-Waiver" to prescribe buprenorphine in the treatment of opioid use disorders.

Course Objectives:

Participants will be instructed in:

- History of medication assisted treatment for addictive disorders
- Clinical management instruction on the induction and maintenance of patients with opioid use disorders using buprenorphine (suboxone)

Certificate of Completion:

Following the in-person training, participants will be provided with a link to complete five on-line modules (approximately 4 hours). By completing the in-person training, the on-line self-study and a self-assessment, participants will have satisfied requirements to obtain DEA X-Waiver to prescribe buprenorphine/buprenorphine-naloxone in the treatment of opioid use disorders. Instructions and guidance will be provided for completing the necessary paperwork.

NPs and PAs are required to complete additional online or in person trainings to complete all requirements necessary for waiver. The additional 16 hours of training is available on PCSS at no cost: <https://pcssnow.org/education-training/mat-training/>



Instructor:

Jeffrey J. DeVido, M.D., M.T.S.
Chief, Addiction Services, Marin County

Dept. of Health and Human Services, Behavioral Health and Recovery Services.
Assistant Clinical Professor, UCSF Dept. of Psychiatry.
Board Certified: Adult Psychiatry, Addiction Psychiatry & Addiction Medicine.

Funding for this initiative was made possible (in part) by grant nos. 5U79TI026556-02 and 3U79TI026556-02S1 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government



Questions?
Contact:
mnaish@rchc.net